By: Lana Volokh
CEO
Share

ExoProTher Medical

ExoProTher Medical is an Israeli biotech company, developing a breakthrough bio-therapy that targets 60% of human cancers. The company has achieved strong positive results in pre-clinical trials with no adverse effects.

202%

From funding target

19

Investors

0

Days to go
Type:Convertible  
Stage:Seed
Category:Healthcare
•  Successfully funded    
  • Campaign Highlights
  • Pitch
  • Team
  • Investors 19
  • Updates

Campaign Highlights

First In Class Biological Treatment for 60% of Cancer Cases

ExoProTher’s revolutionary solution - EXO - targets all human cancers with mutation of p53 gene, which is known as “guardian of the genome”. P53 mutation can be found in up to 60% of human cancers regardless of their location in the body. This innovative treatment will help to treat the most aggressive and deadly cancers, including glioblastoma (brain cancer), colon cancer, bladder cancer, ovarian cancer and small cell lung cancer.

Unique attractive properties

Unlike many existing cancer treatments, EXO is non-toxic and did not cause any side effects in experiments conducted so far.

Furthermore, it was effective in preventing metastases during the experiments.

In addition, EXO is synergistic with existing cancer treatments and may be used as combination treatment.

 

Successful Preclinical Studies

Efficacy of the EXO solution in treating glioblastoma (brain cancer), colon cancer, melanoma (skin cancer) and lung cancer has been proven in a series of laboratory experiments. Subsequently, a preclinical colon cancer study was performed and demonstrated significantly prolonged survival, reduced metastases and none of the adverse effects that commonly accompany most known cancer therapies. A toxicity study has also demonstrated lack of adverse effects even for large doses of EXO.

A Huge and Active Market with Multiple High-Level Acquisition Deals

ExoProTher operates in the cancer bio-therapy market, valued at billions of dollars a year and considered to be the future of oncology therapy. This field of oncology therapies is noted for its multiple acquisitions of early-stage companies. In 2018 alone, ten cancer treatment companies were sold for hundreds of millions to billions of dollars each. Among those Bicycle and Unum Therapeutics, which were acquired while in preclinical stages. Furthermore, while ExoProTher targets About 60% of human cancers are associated with mutation in the gene encoding p53 protein. 

 

Intellectual Property Fully Owned by the Company

In 2017, ExoProTher filed a patent through one of Israel's leading patent offices, Ehrlich and Fenster Patent Attorneys, covering their core technology. An favorable PCT Review was received, stating that all 45 patent claims were novel and inventive. The claims cover material composition, drug delivery and therapeutic schemes. The patent is now in National Phase in multiple countries.

Pitch

The idea

Cancer is one of the major killers in the world; it accounts for nearly 1 in 6 deaths globally. While billions of dollars are being spent on cancer research, many cancers still do not have a cure, and the number of deaths from cancer is expected to continue rising in years to come.

The Need

About 60% of human cancers are caused by mutation in the gene encoding p53 protein. This protein is often referred to as ”guardian of the genome”. Damage to this mechanism leads to destruction of a cell's defense mechanism, and thus any further mutation can cause development of malignancy.The importance of p53 function has been known to scientists for decades, and many have tried to provide healthy human p53 to the cancer cells in order to repair the damage.  Still, up to date, no effective way to do so has been found.

 

The Solution

ExoProTher takes a completely novel approach to cancer therapy by using natural nano-particles - exosomes to deliver healthy p53 to malignant cells and restore the body’s natural tumor suppression function with minimal adverse effects.

Exosomes can easily penetrate the BBB (blood-brain barrier) and deliver treatment for glioblastoma (the deadliest kind of brain cancer) even by inhalation.

Initial indications pursued by the company target the deadliest cancer types with the highest rate of p53 mutation, such as brain cancer, lung cancer and colon cancer.

Harnessing Evolution to Fight Cancer: ExoProTher's nano-particles, which are the basis for the treatment, are harvested from tissues where cancer occurrence is extremely low. ExoProTher is, in fact, using an ancient biological mechanism that suppresses cancer development in immediate vicinity of these tissues turning it into a breakthrough systemic treatment applied to any location in the body.

It is important to note that exosomes are non-toxic and not immunogenic (do not trigger an immune response) and, therefore, do not cause side effects. EXO may reduce, and possibly even eliminate, the need for conventional treatments such as radiation and chemotherapy, which are so damaging to the body.

All of this makes ExoProTher's treatment revolutionary and the first of its kind in the world.

ExoProTher will be pursuing breakthrough therapy designation from the FDA and accelerated access to clinical trials.

 

The Technology

ExoProTher technology brings two major innovations:

Novel use of native nanoparticles – exosomes - as a vehicle to deliver p53 protein to cancer cells. The idea originates from a newly discovered mechanism that has existed for millions of years  in all vertebrates. It is widely known that malignant mutations can be caused by carcinogens, such as exposure to UV rays (ultraviolet radiation). Approximately 90% of skin cancers appear in sun exposed areas. Surprisingly, cancer development is extremely rare in the eyes, the organ also exposed to UV radiation. It turns out that in some tissues the amount of p53 protein, which prevents cancer development, is extremely high. In addition, in these tissues the p53, along with other tumor suppressors, is packed in exosomes capable of moving from cell to cell. Thus, if p53 in one cell in such tissue is damaged and does not protect it from further mutations, the cell receives healthy p53 from neighboring cells. ExoProTher researchers have proposed a unique way to produce and use exosomes loaded with active and healthy p53 as a breakthrough treatment for the most lethal cancers.

  1. Only 26% of glioblastoma (GBM) cells remain viable following a single application of EXO.  
  2. One of the biggest challenges in drug delivery to the brain is the blood-brain barrier (BBB) - a biological obstacle that makes it extremely difficult to treat brain cancers, such as glioblastoma. Professor Danny Offen from Tel Aviv University and Beilinson Hospital, an Israeli expert on exosomes and a scientific adviser to the company, mentions that, based on previous research, exosomes are able to pass the BBB and reach areas of the disease.
  3. The graph above shows significant reduction of cancer cells viability following a single application of the therapeutic substance. (The experiment was conducted at the Integrated Cancer Prevention Center of the Souratsky Medical Center).

Exosome-based treatment is very attractive due to their native properties:

  • Stable (stay in the system long enough to be effective)
  • Non-toxic and non-immunogenic
  • Able to pass BBB (blood-brain barrier), even using nasal inhalation
  • Possesses natural ability to enter cells
  • Can be used in conjunction with conventional treatments

Recently, the potential of exosomes as an oncology treatment delivery vehicle has been highlighted in a number of visionary papers. The technologies are still in an early stage of development and are being actively pursued by several companies. ExoProTher uniquely benefits from the experience of its scientific advisor, Prof. Daniel Offen, founder of successful cell therapy companies. Prof. Offen contributes expertise in exosome-based treatment accumulated in the field of neurodegenerative diseases.

 

  1. Utilization of animal origin p53, instead of human. Use of animal origin protein solves one of the key problems hampering previous attempts of p53 function restoration. It has been found that even if one can deliver a healthy human p53 protein to cancer cells, it undergoes aggregation with the mutant protein and is unable to perform its function. The structure of animal protein is slightly different, preventing its connection with the mutant human protein but still allowing it to perform its designated function.It should be noted that multiple therapies derived from animal tissues have been previously approved by the FDA and are now widely used in a variety of therapeutic areas.

 

Experimental Results

ExoProTher has established a laboratory that serves as facility for production of the therapeutic material. In the course of preclinical studies the team worked with leading research laboratories in Israel.

In-Vitro Experiments (Cell Lines)

Efficacy of the treatment on glioblastoma, colon cancer, melanoma (skin cancer) and lung cancer was demonstrated in laboratory experiments.

After 24 hours, cancer cell death can clearly be seen in the control group, following the delivery of one dose of EXO_002 substance.

 

 

In-Vivo Experiment (animal testing) - Effectiveness and Toxicology

ExoProTher completed successful preclinical studies, results of which showed a doubling of life expectancy and reduction in metastases in colon cancer. A toxicity trial was also performed, showing a complete absence of side effects.

 

 

Team

Lana Volokh
Co-founder & CEO
Biography
Dr. Lana Volokh has 18 years of experience in healthcare industry in variety of positions including R&D, system engineering, advanced technologies management, clinical research management, product, clinical and regulatory strategy development and management. She has worked in corporate (GE Healthcare, Israel and USA), academic (Johns Hopkins University) and start-up (Arineta, and more) environments. Dr. Volokh has been key contributor to development of a number of products combining high technology and clinical components. (GE Healthcare Israel and USA, Johns Hopkins University)

  • Founder
Alex Tendler
Co-founder & CTO
Biography
Dr. Alex Tendler is a entrepreneur, scientist and researcher with vast experience in management of international projects in various areas of life sciences and biomedical engineering such as drug delivery, neuroscience and medical devices. He has extensive experience in leading multidisciplinary projects from concept development to clinical research, including IP development, scientific writing, and teaching. Dr. Tendler has deep knowledge of a wide range of research methods and techniques, including designing and monitoring laboratory and clinical trials and has led multiple innovative research and development teams. (Intel, Technion, University of Haifa, Rainbow Medical)

  • Founder
Yevgeny Tendler
Chief Scientist
Biography
Dr. Tendler is a scientist, expert in cell biology with over 30 years experience in the field. Author of multiple scientific publications. ( Dep. Of Clinical Biochemistry, Rambam Medical Center, ret.)

  • Key Employee
Shay Wail
VP BD
Biography
Shay Wail is serial entrepreneur, Investor, advisor, and board member of start-ups in the tech and medical fields. Shay has extensive experience in early development of AR/VR/MR optical applications. Shay has large experience in strategic planning and business development, working for international corporations such as Apple, Intel and Broadcom as well as early stage start-ups.

  • Key Employee
Daniel Offen,
Advisor
Biography
Dr. Daniel Offen is an internationally recognized researcher, inventor, innovator and  co-founder of several biotechnology companies. Dr. Offen co-authored multiple research publications and is Head of Translational Neuroscience Laboratory at TAU

  • Advisor
Alexander Panshin
Advisor
Biography
Dr. Alex Panshin is a researcher, specialist in molecular biology, immunology and allergology with oncology applications. He has published multiple articles on these subjects. Dr. Panshin worked in the Department of Avian Diseases, the Kimron (ret.)

  • Advisor
Avi Treves
Advisor
Biography
Dr. Treves is an expert in translational and clinical R&D, product development, one of pioneers of immuno-oncology and cell therapy, co-founder of several biotech companies, including NASDAQ traded Gamida-Cell. Dr. Treves is member of The Israeli Ministry of Health Committee for Registering of Cellular Based Therapies. Previously served as Deputy Director of the Sheba Cancer Research Center and member of Ella Lemelbaum Institute for Tumor Immunology, Sheba Medical Center

  • Advisor
Yoav Levinger
Marketing & Process Solutions
Biography
Yoav Levinger is an experienced entrepreneur with more than 15 years experience in R&D Management, leading Software development, DevOps, digital marketing, business development, quality and regulations.

  • Key Employee

The Deal

Documents

Disclosures

Investors 19

Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
2
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
10
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
5
Investments
Anonymous Investor
0
Followers
3
Investments
Anonymous Investor
0
Followers
5
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
2
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
1
Followers
16
Investments

Updates

Currently there are no updates in this pitch

Need help?
The financing rounds made through the ExitValley platform are in accordance with a model of statutory exemption from publishing a prospectus pursuant to sections 15A(A)(1) and 15A(A)(7) to the Israeli companies law - 1965.
Under our model, the disclosure of detailed information on the company and information about the investment in each round of financing are limited to not more than 35 investors which are not qualified investors and the round of financing in not in the format of an offering arrangement ("רכז הצעה") as defined in the securities law
Follow us